Torrey Pines Institute for Molecular Studies And The Tri-Institutional Therapeutics Discovery Institute Announce Strategic Agreement
PORT ST. LUCIE, Fla., July 25, 2017 /PRNewswire-USNewswire/ -- Torrey Pines Institute for Molecular Studies, Inc. (TPIMS) today announced a strategic agreement with The Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI). TPIMS has built a collection of compounds and corresponding technologies enabling the rapid screening of up to trillions of unique compounds by testing only hundreds of samples to identify individual hit compounds for development. The mission of the Tri-I TDI is to advance groundbreaking biological discoveries to preclinical studies by providing industrial-scale technical support for academic projects, making it possible to rapidly assess the utility of specific therapeutic targets in disease-relevant contexts.
"We are pleased to partner with Tri-I TDI and provide our compound collection," said Richard Houghten, Ph.D., Founder and CEO, TPIMS. "Our technologies can enable high-throughput screening in a variety of biological assay formats, including phenotypic assays. This collaboration aims to accelerate drug discovery, ultimately providing new therapies to treat human diseases."
Through this partnership, TPIMS will provide Tri-I TDI with the TPIMS compound collection for screening to identify hit compounds within Tri-I TDI research programs. This provides Tri-I TDI with capabilities to perform high-throughput screening across a variety of assay platforms with TPIMS' unique compound collection.
"We believe that access to the TPIMS compound collection will enhance our ability to deliver on our mission. Leads from these collections should enable the progression of groundbreaking academic discoveries to preclinical studies in order to demonstrate their relevance in blocking disease initiation and progression," stated Peter T. Meinke, Ph.D., VP, Preclinical Development, Tri-I TDI.
About the Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI)
The Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) connects researchers from Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine with collaborators from across the globe to remove the barriers that impede drug discovery in academic settings. Together with its partners, Takeda Pharmaceuticals and Bridge Medicines, the Tri-I TDI enables the discovery of next-generation drugs by empowering faculty with the tools, technology, and expertise to meet this extraordinary challenge. This partnership leverages combined resources to help academic researchers rapidly advance their groundbreaking discoveries along the path from bench to bedside.
About Torrey Pines Institute for Molecular Studies (TPIMS)
Torrey Pines Institute for Molecular Studies (TPIMS) is a non-profit institute dedicated to conducting basic research to advance the understanding of human disease and the improvement of human health. TPIMS' scientists conduct research in fields associated with a wide variety of major medical conditions, including addiction, Alzheimer's, arthritis, cancer, diabetes, heart disease, infectious disease, inflammatory disorders, multiple sclerosis, obesity, pain management, regenerative medicine and new methods for drug discovery.
Contact:
Greg Welmaker, Ph.D., MBA
President, COO, & Director of Drug Discovery
Phone: 772-345-4582
Email: tpimsnews@tpims.org
View original content:http://www.prnewswire.com/news-releases/torrey-pines-institute-for-molecular-studies-and-the-tri-institutional-therapeutics-discovery-institute-announce-strategic-agreement-300492798.html
SOURCE Torrey Pines Institute for Molecular Studies, Inc.
